125 related articles for article (PubMed ID: 19377291)
21. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
[TBL] [Abstract][Full Text] [Related]
22. Stability of an aluminum salt-adjuvanted protein D-conjugated pneumococcal vaccine after exposure to subzero temperatures.
Fortpied J; Wauters F; Rochart C; Hermand P; Hoet B; Moniotte N; Vojtek I
Hum Vaccin Immunother; 2018 May; 14(5):1243-1250. PubMed ID: 29337646
[TBL] [Abstract][Full Text] [Related]
23. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants.
Shi L; Sanyal G; Ni A; Luo Z; Doshna S; Wang B; Graham TL; Wang N; Volkin DB
J Pharm Sci; 2005 Jul; 94(7):1538-51. PubMed ID: 15929070
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.
Petäjä T; Keränen H; Karppa T; Kawa A; Lantela S; Siitari-Mattila M; Levänen H; Tocklin T; Godeaux O; Lehtinen M; Dubin G
J Adolesc Health; 2009 Jan; 44(1):33-40. PubMed ID: 19101456
[TBL] [Abstract][Full Text] [Related]
25. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.
; Romanowski B; de Borba PC; Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; Aoki F; Ramjattan B; Shier RM; Somani R; Barbier S; Blatter MM; Chambers C; Ferris D; Gall SA; Guerra FA; Harper DM; Hedrick JA; Henry DC; Korn AP; Kroll R; Moscicki AB; Rosenfeld WD; Sullivan BJ; Thoming CS; Tyring SK; Wheeler CM; Dubin G; Schuind A; Zahaf T; Greenacre M; Sgriobhadair A
Lancet; 2009 Dec; 374(9706):1975-85. PubMed ID: 19962185
[TBL] [Abstract][Full Text] [Related]
26. Disassembly and reassembly improves morphology and thermal stability of human papillomavirus type 16 virus-like particles.
Zhao Q; Allen MJ; Wang Y; Wang B; Wang N; Shi L; Sitrin RD
Nanomedicine; 2012 Oct; 8(7):1182-9. PubMed ID: 22306156
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial.
Konno R; Tamura S; Dobbelaere K; Yoshikawa H
Int J Gynecol Cancer; 2010 Jul; 20(5):847-55. PubMed ID: 20606533
[TBL] [Abstract][Full Text] [Related]
28. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.
Einstein MH; Takacs P; Chatterjee A; Sperling RS; Chakhtoura N; Blatter MM; Lalezari J; David MP; Lin L; Struyf F; Dubin G;
Hum Vaccin Immunother; 2014; 10(12):3435-45. PubMed ID: 25483701
[TBL] [Abstract][Full Text] [Related]
29. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
32. Analytical and Preformulation Characterization Studies of Human Papillomavirus Virus-Like Particles to Enable Quadrivalent Multi-Dose Vaccine Formulation Development.
Jerajani K; Wan Y; Hickey JM; Kumru OS; Sharma N; Pullagurla SR; Ogun O; Mapari S; Whitaker N; Brendle S; Christensen ND; Batwal S; Mahedvi M; Rao H; Dogar V; Chandrasekharan R; Shaligram U; Joshi SB; Volkin DB
J Pharm Sci; 2022 Nov; 111(11):2983-2997. PubMed ID: 35914546
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
35. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10- to 14-year-old girls: open 6-year follow-up of an initial observer-blinded, randomized trial.
Schwarz TF; Huang LM; Lin TY; Wittermann C; Panzer F; Valencia A; Suryakiran PV; Lin L; Descamps D
Pediatr Infect Dis J; 2014 Dec; 33(12):1255-61. PubMed ID: 24978856
[TBL] [Abstract][Full Text] [Related]
36. [Quantitative analysis of nine types of virus-like particles in human papilloma virus bulk by size-exclusion chromatography].
Long Z; Li X; Li X; Liu J; Nie J; Li C; Li Y; Huang T; Huang W
Se Pu; 2021 Apr; 39(4):424-429. PubMed ID: 34227763
[TBL] [Abstract][Full Text] [Related]
37. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
[TBL] [Abstract][Full Text] [Related]
38. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.
Giannini SL; Hanon E; Moris P; Van Mechelen M; Morel S; Dessy F; Fourneau MA; Colau B; Suzich J; Losonksy G; Martin MT; Dubin G; Wettendorff MA
Vaccine; 2006 Aug; 24(33-34):5937-49. PubMed ID: 16828940
[TBL] [Abstract][Full Text] [Related]
39. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials.
Descamps D; Hardt K; Spiessens B; Izurieta P; Verstraeten T; Breuer T; Dubin G
Hum Vaccin; 2009 May; 5(5):332-40. PubMed ID: 19221517
[TBL] [Abstract][Full Text] [Related]
40. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up.
Roteli-Martins CM; Naud P; De Borba P; Teixeira JC; De Carvalho NS; Zahaf T; Sanchez N; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2012 Mar; 8(3):390-7. PubMed ID: 22327492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
